Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT02205047
Title Neoadjuvant Study Using Trastuzumab or Trastuzumab With Pertuzumab in Gastric or Gastroesophageal Junction Adenocarcinoma (INNOVATION)
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors European Organisation for Research and Treatment of Cancer - EORTC

gastroesophageal junction adenocarcinoma

gastric adenocarcinoma


Capecitabine + Cisplatin

Cisplatin + Fluorouracil + Pertuzumab + Trastuzumab

Cisplatin + Fluorouracil

Cisplatin + Fluorouracil + Trastuzumab

Capecitabine + Cisplatin + Trastuzumab

Capecitabine + Cisplatin + Pertuzumab + Trastuzumab

Age Groups: senior | adult
Covered Countries ITA | FRA | ESP | DEU | BEL

No variant requirements are available.